This is the first known human documented with a GLP2R‐deficient phenotype, resulting in clinical illness, which correlates with the findings in the GLP2R mouse knockout model and furthers our understanding of GLP2R and the action of teduglutide, a GLP2 analog used for the treatment of short bowel syndrome. The gene discussed is GLP2R; the disease is short bowel syndrome.